The Menin Inhibitor Landscape in AML: Setting the Clinical Stage

In this episode, Amir Ali, PharmD, BCOP, explains the role of menin inhibitors in treating relapsed/refractory AML driven by KMT2A translocations and NPM1 mutations. He discusses how these agents disrupt the menin–MLL1 interaction and highlights the key regulatory differences between revumenib and ziftomenib—including which agent is approved for which patient populations and mutations—to help pharmacists verify orders accurately from the start.